Esophageal Cancer Staging MCQ — NEET PG Practice Question | NEETPGAI
Esophageal Cancer Staging
medium
scissors Surgery
A 60-year-old male smoker with 3 months of progressive dysphagia and 8 kg weight loss undergoes upper GI endoscopy revealing a circumferential ulcerated mass at 28 cm from incisors. Contrast-enhanced CT chest shows asymmetric wall thickening (16 mm) of the mid-thoracic esophagus with **loss of fat plane around the periesophageal soft tissue but preserved fat planes around the aorta and tracheobronchial tree**. Multiple 12–15 mm subcarinal and right paratracheal nodes are noted. Biopsy confirms squamous cell carcinoma. The structure marked **B** in the diagram represents this locally advanced mid-esophageal tumor. According to AJCC 8th-edition T-staging, which of the following is the most appropriate next step in management for this T3 N1 M0 disease?
A. Neoadjuvant chemoradiotherapy (carboplatin/paclitaxel + 41.4 Gy) followed by transthoracic esophagectomy 6–8 weeks later
B. Immediate transthoracic esophagectomy without neoadjuvant therapy
C. Palliative chemotherapy with close surveillance
D. Definitive chemoradiation alone without surgery
Explanation
Why neoadjuvant chemoradiotherapy followed by transthoracic esophagectomy is correct
The structure marked B represents T3 mid-esophageal squamous cell carcinoma with invasion of periesophageal fat (loss of fat plane) and N1 nodal disease. Per the AJCC 8th edition, T3 is defined as invasion of the adventitia with periesophageal fat involvement—exactly what the CT demonstrates. The CROSS trial established that locally advanced esophageal cancer (T3–T4a/N+) is best managed with neoadjuvant chemoradiotherapy (carboplatin/paclitaxel + 41.4 Gy) followed by transthoracic esophagectomy (Ivor Lewis or McKeown) 6–8 weeks later. This multimodal approach improves overall survival and R0 resection rates in mid-thoracic tumors.
Why each distractor is wrong
Definitive chemoradiation alone without surgery: Reserved for cervical esophageal cancers (above the suprasternal notch) or medically unfit patients. Mid-thoracic T3 N1 disease is resectable and benefits from surgical resection after neoadjuvant therapy per CROSS.
Immediate transthoracic esophagectomy without neoadjuvant therapy: Upfront surgery without neoadjuvant chemoradiotherapy is associated with worse outcomes and higher morbidity in locally advanced disease. Neoadjuvant therapy downstages the tumor and improves R0 resection rates.
Palliative chemotherapy with close surveillance: Inappropriate for a fit 60-year-old with resectable T3 N1 M0 disease. Palliative intent is reserved for unresectable (T4b) or metastatic disease.
High-YieldNEET PG
T3 esophageal cancer = adventitial invasion with periesophageal fat involvement; mid-thoracic T3 N+ disease → CROSS protocol (neoadjuvant chemoradiotherapy + esophagectomy); cervical T3 → definitive chemoradiation.
